Article

Viral dynamics in hepatitis B virus infection.

Department of Zoology, University of Oxford, United Kingdom
Proceedings of the National Academy of Sciences (Impact Factor: 9.81). 05/1996; 93(9):4398-402. DOI: 10.1073/pnas.93.9.4398
Source: PubMed

ABSTRACT Treatment of chronic hepatitis B virus (HBV) infections with the reverse transcriptase inhibitor lamivudine leads to a rapid decline in plasma viremia and provides estimates for crucial kinetic constants of HBV replication. We find that in persistently infected patients, HBV particles are cleared from the plasma with a half-life of approximately 1.0 day, which implies a 50% daily turnover of the free virus population. Total viral release into the periphery is approximately 10(11) virus particles per day. Although we have no direct measurement of the infected cell mass, we can estimate the turnover rate of these cells in two ways: (i) by comparing the rate of viral production before and after therapy or (ii) from the decline of hepatitis B antigen during treatment. These two independent methods give equivalent results: we find a wide distribution of half-lives for virus-producing cells, ranging from 10 to 100 days in different patients, which may reflect differences in rates of lysis of infected cells by immune responses. Our analysis provides a quantitative understanding of HBV replication dynamics in vivo and has implications for the optimal timing of drug treatment and immunotherapy in chronic HBV infection. This study also represents a comparison for recent findings on the dynamics of human immunodeficiency virus (HIV) infection. The total daily production of plasma virus is, on average, higher in chronic HBV carriers than in HIV-infected patients, but the half-life of virus-producing cells is much shorter in HIV. Most strikingly, there is no indication of drug resistance in HBV-infected patients treated for up to 24 weeks.

1 Bookmark
 · 
130 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: The development of innovative drugs is becoming more difficult while relying on empirical approaches. This inspired all major pharmaceutical companies to pursue alternative model-based paradigms. The key question is: How to find innovative compounds and, subsequently, appropriate dosage regimens? Written from the industry perspective and based on many years of experience, this book offers: - Concepts for creation of drug-disease models, introduced and supplemented with extensive MATLAB programs - Guidance for exploration and modification of these programs to enhance the understanding of key principles - Usage of differential equations to pharmacokinetic, pharmacodynamic and (patho-) physiologic problems thereby acknowledging their dynamic nature - A range of topics from single exponential decay to adaptive dosing, from single subject exploration to clinical trial simulation, and from empirical to mechanistic disease modeling. Students with an undergraduate mathematical background or equivalent education, interest in life sciences and skills in a high-level programming language such as MATLAB, are encouraged to engage in model-based pharmaceutical research and development.
    01/2014; Springer-Verlag Berlin Heidelberg., ISBN: 978-3-642-39764-6
  • [Show abstract] [Hide abstract]
    ABSTRACT: Human hepatitis B virus (HBV) is the prototype of a family of small DNA viruses that productively infect hepatocytes, the major cell of the liver, and replicate by reverse transcription of a terminally redundant viral RNA, the pregenome. Upon infection, the circular, partially double-stranded virion DNA is converted in the nucleus to a covalently closed circular DNA (cccDNA) that assembles into a minichromosome, the template for viral mRNA synthesis. Infection of hepatocytes is non-cytopathic. Infection of the liver may be either transient (<6 months) or chronic and lifelong, depending on the ability of the host immune response to clear the infection. Chronic infections can cause immune-mediated liver damage progressing to cirrhosis and hepatocellular carcinoma (HCC). The mechanisms of carcinogenesis are unclear. Antiviral therapies with nucleoside analog inhibitors of viral DNA synthesis delay sequelae, but cannot cure HBV infections due to the persistence of cccDNA in hepatocytes. Copyright © 2015 Elsevier Inc. All rights reserved.
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The evolution rates of the hepatitis B virus (HBV) estimated using contemporary sequences are 102-104 times faster than those derived from archaeological and genetic evidence. This discrepancy makes the origin of HBV and time scale of its spread, both of which are critical for studying the burden of HBV pathogenicity, remains largely unresolved. To evaluate whether the dual demands (i.e., adaptation within hosts and colonization between hosts) of the viral life cycle affect this conundrum, the HBV quasispecies dynamics within and among hosts from a family consisting of a grandmother, her 5 children, and her 2 granddaughters, all of whom presumably acquired chronic HBV through mother-to-infant transmission, were examined by PCR cloning and next generation sequencing methods. We found that evolutionary rate of HBV between hosts was considerably lower than that of within hosts. Moreover, the between-host substitution rates of the HBV decreased as transmission numbers between individual increased. Both observations were primarily due to changes at nonsynonymous rather than synonymous sites. There were significantly more multiple substitutions than expected under random mutation process and 97% of substitutions were changed from common to rare amino acid residues in the database. Continual switching between colonization and adaptation resulted in the rapid accumulation of mutations at a limited number of positions, which quickly became saturated, whereas substitutions at the remaining regions occurred at a much slower rate. Our study may help to explain the time-dependent HBV substitution rates reported in the literature and provide new insights into the origin of the virus. IMPORTANCE: It is known that the estimated hepatitis B virus (HBV) substitution rate is time-dependent, but the reason behind is still elusive. We hypothesize that, owing to their small genome size, the transmission between hosts and adaptation within hosts must exhibit high levels of fitness tradeoffs for the viruses. By studying the HBV quasispecies dynamics from a chain of sequentially infected transmissions within a family, we found HBV substitution rate between patients to be negatively correlated with the number of transmissions. Continual switching between hosts resulted in the rapid accumulation of mutations at a limited number of genomic sites, which quickly became saturated in the short-term. Nevertheless, substitutions at the remaining regions occurred at a much slower rate. Therefore, the HBV substitution rate decreased as the divergence time increased.
    Journal of Virology 11/2014; DOI:10.1128/JVI.03131-14 · 4.65 Impact Factor

Full-text (2 Sources)

Download
37 Downloads
Available from
May 23, 2014